Rekombinanter ErbB2/Her2 Antikörper
Kurzübersicht für Rekombinanter ErbB2/Her2 Antikörper (ABIN7795221)
Target
Alle ErbB2/Her2 Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
Klon
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- In vivo Grade Recombinant Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody, Mouse IgG1 Kappa
-
Produktmerkmale
- Trastuzumab, a humanized monoclonal antibody (clone HuMAb 4D5-8), interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
-
Andere Bezeichnung
- HER2
-
Pathways
- RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Skeletal Muscle Fiber Development
Target
-